RARE
Ultragenyx Pharmaceutical Inc.

2,462
Mkt Cap
$3.23B
Volume
1.00
52W High
$53.47
52W Low
$25.81
PE Ratio
-6.05
RARE Fundamentals
Price
$33.47
Prev Close
$34.60
Open
$34.00
50D MA
$31.33
Beta
1.04
Avg. Volume
1.35M
EPS (Annual)
-$6.29
P/B
21.28
Rev/Employee
$432,944.36
Loading...
Loading...
News
all
press releases
Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·6d ago
News Placeholder
More News
News Placeholder
Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·7d ago
News Placeholder
Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength?
DBV Technologies (DBVT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·18d ago
News Placeholder
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
Zacks·1mo ago
News Placeholder
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.
Zacks·2mo ago
News Placeholder
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.
Zacks·2mo ago
News Placeholder
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.
Zacks·3mo ago
News Placeholder
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·3mo ago
News Placeholder
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains?
BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·3mo ago

Latest RARE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.